Specify a stock or a cryptocurrency in the search bar to get a summary
Tenaya Therapeutics Inc
TNYATenaya Therapeutics, Inc., a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage. It also develops an adeno-associated virus-based gene therapy designed to deliver the dworf gene for patient with dilated cardiomyopathy; and reprogramming program for heart failure due to prior myocardial infarction. Tenaya Therapeutics, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California. Address: 171 Oyster Point Boulevard, South San Francisco, CA, United States, 94080
Analytics
WallStreet Target Price
19.43 USDP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures TNYA
Dividend Analytics TNYA
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History TNYA
Stock Valuation TNYA
Financials TNYA
Results | 2019 | Dynamics |